These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8040124)

  • 1. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies.
    Caillot D; Reny G; Solary E; Casasnovas O; Chavanet P; Bonnotte B; Perello L; Dumas M; Entezam F; Guy H
    J Antimicrob Chemother; 1994 Mar; 33(3):603-13. PubMed ID: 8040124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients.
    Moreau P; Milpied N; Fayette N; Ramée JF; Harousseau JL
    J Antimicrob Chemother; 1992 Oct; 30(4):535-41. PubMed ID: 1490923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients.
    Nucci M; Loureiro M; Silveira F; Casali AR; Bouzas LF; Velasco E; Spector N; Pulcheri W
    Antimicrob Agents Chemother; 1999 Jun; 43(6):1445-8. PubMed ID: 10348768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis.
    Joly V; Aubry P; Ndayiragide A; Carrière I; Kawa E; Mlika-Cabanne N; Aboulker JP; Coulaud JP; Larouze B; Yeni P
    Clin Infect Dis; 1996 Sep; 23(3):556-62. PubMed ID: 8879780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Intralipid infusion in reducing amphotericin-B-associated nephrotoxicity in head and neck invasive fungal infection: A randomized, controlled trial.
    Hasibi M; Jafari S; Manshadi SA; Asadollahi M; Salehi M; Zarch VV; Kouhi A
    Ear Nose Throat J; 2017 Feb; 96(2):E18-E22. PubMed ID: 28231371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion.
    Nath CE; Shaw PJ; Gunning R; McLachlan AJ; Earl JW
    Antimicrob Agents Chemother; 1999 Jun; 43(6):1417-23. PubMed ID: 10348763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.
    Pascual B; Ayestaran A; Montoro JB; Oliveras J; Estibalez A; Julia A; Lopez A
    Ann Pharmacother; 1995 Dec; 29(12):1197-201. PubMed ID: 8672820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
    Schöffski P; Freund M; Wunder R; Petersen D; Köhne CH; Hecker H; Schubert U; Ganser A
    BMJ; 1998 Aug; 317(7155):379-84. PubMed ID: 9694753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients.
    Sorkine P; Nagar H; Weinbroum A; Setton A; Israitel E; Scarlatt A; Silbiger A; Rudick V; Kluger Y; Halpern P
    Crit Care Med; 1996 Aug; 24(8):1311-5. PubMed ID: 8706484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients?].
    Hernández G; Altermatt F; Bernucci F; Acuña D; Apablaza F; Valenzuela F; Lefio A; Pérez C; Bugedo G; Castillo L
    Rev Med Chil; 2000 Oct; 128(10):1101-7. PubMed ID: 11349508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits.
    Chavanet P; Duong M; Buisson M; Hamel H; Dubois C; Bonnin A; Portier H
    J Antimicrob Chemother; 1997 Mar; 39(3):427-30. PubMed ID: 9096196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients.
    Barquist E; Fein E; Shadick D; Johnson J; Clark J; Shatz D
    J Trauma; 1999 Aug; 47(2):336-40. PubMed ID: 10452470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.
    Chavanet PY; Garry I; Charlier N; Caillot D; Kisterman JP; D'Athis M; Portier H
    BMJ; 1992 Oct; 305(6859):921-5. PubMed ID: 1458072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients.
    Caillot D; Casasnovas O; Solary E; Chavanet P; Bonnotte B; Reny G; Entezam F; Lopez J; Bonnin A; Guy H
    J Antimicrob Chemother; 1993 Jan; 31(1):161-9. PubMed ID: 8444659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.
    Ayestarán A; López RM; Montoro JB; Estíbalez A; Pou L; Julià A; López A; Pascual B
    Antimicrob Agents Chemother; 1996 Mar; 40(3):609-12. PubMed ID: 8851579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotoxicity of amphotericin B administered to dogs in a fat emulsion versus five percent dextrose solution.
    Randall SR; Adams LG; White MR; DeNicola DB
    Am J Vet Res; 1996 Jul; 57(7):1054-8. PubMed ID: 8807021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients.
    Joly V; Geoffray C; Reynes J; Goujard C; Méchali D; Maslo C; Raffi F; Yeni P
    J Antimicrob Chemother; 1996 Jul; 38(1):117-26. PubMed ID: 8858463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amphotericin B toxicity reduced by administration in fat emulsion.
    Anderson RP; Clark DA
    Ann Pharmacother; 1995 May; 29(5):496-500. PubMed ID: 7655134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B.
    Caillot D; Chavanet P; Casasnovas O; Solary E; Zanetta G; Buisson M; Wagner O; Cuisenier B; Bonnin A; Camerlynck P
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):722-5. PubMed ID: 1425731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of salt supplementation on amphotericin B nephrotoxicity.
    Llanos A; Cieza J; Bernardo J; Echevarria J; Biaggioni I; Sabra R; Branch RA
    Kidney Int; 1991 Aug; 40(2):302-8. PubMed ID: 1942779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.